Contents

Contents

• Perspective

  • Beyond 3D culture models of cancer

    By Kandice Tanner, Michael M. Gottesman

    Science Translational Medicine15 Apr 2015 : 283ps9 Full AccessRestricted Access

    Three-dimensional culture models can represent cancer and its microenvironment and provide a platform for pharmaceutical testing.

    • Abstract
    • Full Text
    • PDF

• Research Articles

  • PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

    By Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Aleix Prat, Jessica J. Tao, Daniel E. Spratt, Nerissa T. Viola-Villegas, Pau Castel, Gerard Minuesa, Natasha Morse, Jordi Rodón, Yasir Ibrahim, Javier Cortes, Jose Perez-Garcia, Patricia Galvan, Judit Grueso, Marta Guzman, John A. Katzenellenbogen, Michael Kharas, Jason S. Lewis, Maura Dickler, Violeta Serra, Neal Rosen, Sarat Chandarlapaty, Maurizio Scaltriti, José Baselga

    Science Translational Medicine15 Apr 2015 : 283ra51 Full AccessRestricted Access

    Inhibition of the PI3K/AKT pathway results in induction of ER-dependent transcriptional activity and susceptibility to anti-estrogen therapy in ER-positive breast cancer.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF
    • Supplementary Materials

  • STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

    By Juan Fu, David B. Kanne, Meredith Leong, Laura Hix Glickman, Sarah M. McWhirter, Edward Lemmens, Ken Mechette, Justin J. Leong, Peter Lauer, Weiqun Liu, Kelsey E. Sivick, Qi Zeng, Kevin C. Soares, Lei Zheng, Daniel A. Portnoy, Joshua J. Woodward, Drew M. Pardoll, Thomas W. Dubensky, Jr., Young Kim

    Science Translational Medicine15 Apr 2015 : 283ra52 Full AccessRestricted Access

    Cyclic dinucleotide formulated cancer vaccine combined with PD-1 blockade can induce regression of tumors that do not express PD-L1 constitutively.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF
    • Supplementary Materials

  • Personalized genomic analyses for cancer mutation discovery and interpretation

    By Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica Nesselbush, David R. Riley, Manish Shukla, Bryan Chesnick, Maura Kadan, Eniko Papp, Kevin G. Galens, Derek Murphy, Theresa Zhang, Lisa Kann, Mark Sausen, Samuel V. Angiuoli, Luis A. Diaz, Jr., Victor E. Velculescu

    Science Translational Medicine15 Apr 2015 : 283ra53 Full AccessRestricted Access

    Analysis of matched tumor and normal DNA from the same patient improves accuracy of identification of actionable mutations, allowing better targeting of potential treatments.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF
    • Supplementary Materials

  • Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

    By Nicholas McGranahan, Francesco Favero, Elza C. de Bruin, Nicolai Juul Birkbak, Zoltan Szallasi, Charles Swanton

    Science Translational Medicine15 Apr 2015 : 283ra54 Full AccessRestricted Access

    Pan-cancer analysis of tumor subclonal structures uncovers widespread intratumor heterogeneity in actionable driver events and reveals mutational processes fueling their selection.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF
    • Supplementary Materials

  • Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

    By Michaela Semeraro, Sylvie Rusakiewicz, Véronique Minard-Colin, Nicolas F. Delahaye, David Enot, Frédéric Vély, Aurélien Marabelle, Benjamin Papoular, Christelle Piperoglou, Mirco Ponzoni, Patrizia Perri, Andrei Tchirkov, Jessica Matta, Valérie Lapierre, Tala Shekarian, Sandrine Valsesia-Wittmann, Frédéric Commo, Nicole Prada, Vichnou Poirier-Colame, Brigitte Bressac, Sophie Cotteret, Laurence Brugieres, Françoise Farace, Nathalie Chaput, Guido Kroemer, Dominique Valteau-Couanet, Laurence Zitvogel

    Science Translational Medicine15 Apr 2015 : 283ra55 Full AccessRestricted Access

    Natural killer cell activity and NKp30/B7-H6 interaction are prognostic biomarkers in high-risk neuroblastoma patients.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF
    • Supplementary Materials

• Review

  • The emerging field of mobile health

    By Steven R. Steinhubl, Evan D. Muse, Eric J. Topol

    Science Translational Medicine15 Apr 2015 : 283rv3 Full AccessRestricted Access

    Mobile technologies can transform clinical research and health care worldwide—and save money.

    • Abstract
    • Full Text
    • PDF

• Editors' Choice

  • Of obese mice and monkeys: Protective effects of PI3K inhibition

    By Jessica A. Alvarez

    Science Translational Medicine15 Apr 2015 : 283ec61 Full AccessRestricted Access

    Inhibiting PI3K signaling in obese mice and rhesus monkeys safely reduced adiposity and metabolic abnormalities.

    • Full Text

  • Beating BRAF resistance

    By Sam Behjati

    Science Translational Medicine15 Apr 2015 : 283ec62 Full AccessRestricted Access

    A sequencing study defines resistance mechanisms to BRAF inhibition in colorectal tumors and reveals a possible Achilles’ heel.

    • Full Text

  • Shaping up nicely

    By Kara L. Spiller

    Science Translational Medicine15 Apr 2015 : 283ec63 Full AccessRestricted Access

    Sophisticated imaging reveals that the shape of implanted biomaterials determines their ability to support blood vessel growth.

    • Full Text

  • Singled out: Profiling metabolic and proteomic heterogeneity

    By Ian Y. Wong

    Science Translational Medicine15 Apr 2015 : 283ec64 Full AccessRestricted Access

    A microfluidic assay enables multiplexed single-cell analysis of metabolites and proteins in glioblastoma cells.

    • Full Text